title: [The prolonged administration of intravenous immunoglobulins as a treatment for refractory fistulous Crohn's diseases].
abstract: Fistulating Crohn's disease is present in 17-35% of non-surgically treated patients and in up to 45% of surgically treated ones. Among the several therapeutic alternatives for this disease is intravenous immunoglobulin administration. We present a 28-year-old woman with refractory fistulating Crohn's disease who improved after prolonged immunoglobulin administration (32 months).
authors.affiliation: Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid.
authors.forename: V
authors.initials: V
authors.lastname: González-Lara
authors.forename: J A
authors.initials: JA
authors.lastname: Carneros
authors.forename: O
authors.initials: O
authors.lastname: Núñez-Martínez
authors.forename: C
authors.initials: C
authors.lastname: Rodríguez
authors.forename: M
authors.initials: M
authors.lastname: Escudero
authors.forename: R
authors.initials: R
authors.lastname: Alvarez
mesh_terms: D000328:Adult; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D017577:Cutaneous Fistula / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007077:Ileal Diseases / Q000188:drug therapy* / Q000209:etiology; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007412:Intestinal Fistula / Q000188:drug therapy* / Q000209:etiology; D012074:Remission Induction; D013997:Time Factors; D001747:Urinary Bladder Fistula / Q000188:drug therapy* / Q000209:etiology
chemical_list: D016756:Immunoglobulins, Intravenous